• Pure Global Cannabis (TSXV:PURE) has appointed Scott Langille as the company’s new Chief Financial Officer
  • Mr. Langille will replace previous CFO, Bhupender Gosain, effective immediately
  • Mr. Langille has a wealth of experience in the pharmaceutical and cannabis industry with a range of companies
  • Shares in Pure Global Cannabis are currently trading at 7 cents, with a market cap of C$10.33 million

Pure Global Cannabis (TSXV:PURE) has appointed Scott Langille as its new Chief Financial Officer.

The company is a producer of both branded and white label CBD products, operating via its wholly owned subsidiary, PureSinse.

Mr. Langille will replace Pure Global’s previous CFO, Bhupender Gosain, effective immediately.

According to the announcement, Mr. Gosain was also acting as Corporate Secretary and has left to pursue other opportunities.

Mr. Langille brings a wealth of experience, having most recently served as CFO of Wayland Group – another vertically integrated cannabis operator.

He has also served in CFO roles at Tribute Pharmaceuticals and Virexx Medical, leading several financings in both the pharmaceutical and cannabis industries.

A Certified Management Accountant, Mr. Langille holds an MBA from the University of Toronto and an undergraduate Bachelor of Applied Arts degree from Ryerson University.

“We are excited to have Scott join Pure Global.” said Pure Global CEO, Malay Panchal.

“We believe his deep pharma and cannabis industry knowledge and the experience he has gained makes him an ideal choice to lead our financial strategy.”

Mr. Panchal also made reference to several major financings which, once finalised, are expected to strengthen the company’s balance sheet and ensure short-term liquidity.

“Adding Scott’s extensive skillset strengthens our finance organization and complements our management team as we focus on profitability and building shareholder value,” he continued.

Shares in Pure Global Cannabis are currently trading at 7 cents, with a market cap of C$10.33 million.

More From The Market Online
Cannabis Report image of farmed cannabis plants

The Market Online’s Weekly Cannabis Report – July 26, 2024

Tilray Oral Solution THC10:CBD10 cannabis extract, aka Tilray Solução Oral THC10:CBD10, has been approved for medical use in Portugal.
medical branch logo

Tilray approved for third medical cannabis product in Portugal

Tilray Medical, a subsidiary of Tilray Brands (TSX:TLRY) has been approved for a new medical cannabis extract in Portugal.